StockNews.com Upgrades Cooper Companies (NASDAQ:COO) to “Buy”

StockNews.com upgraded shares of Cooper Companies (NASDAQ:COO) from a hold rating to a buy rating in a research report released on Friday morning.

COO has been the subject of a number of other research reports. Robert W. Baird upped their target price on Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, August 29th. Stifel Nicolaus reiterated a “buy” rating and set a $115.00 target price (up from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Jefferies Financial Group upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating and raised their price target for the stock from $107.00 to $115.00 in a research report on Tuesday, July 16th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research report on Thursday, August 29th. Finally, Piper Sandler upped their target price on Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $117.00.

Cooper Companies Stock Performance

Shares of COO opened at $103.55 on Friday. The company has a 50-day moving average of $107.26 and a two-hundred day moving average of $97.73. The stock has a market cap of $20.62 billion, a price-to-earnings ratio of 57.69, a PEG ratio of 2.24 and a beta of 0.99. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.99 and a quick ratio of 1.18. Cooper Companies has a one year low of $81.99 and a one year high of $112.38.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.91 by $0.05. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $997.30 million. During the same quarter in the prior year, the company earned $0.84 EPS. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. On average, equities research analysts expect that Cooper Companies will post 3.65 earnings per share for the current year.

Insider Buying and Selling at Cooper Companies

In other news, CEO Albert G. White III sold 114,992 shares of the firm’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the sale, the chief executive officer now owns 165,273 shares of the company’s stock, valued at $18,267,624.69. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Cooper Companies news, CEO Albert G. White III sold 114,992 shares of the stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the completion of the transaction, the chief executive officer now owns 165,273 shares in the company, valued at approximately $18,267,624.69. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Agostino Ricupati sold 1,601 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total value of $172,956.03. Following the completion of the sale, the chief accounting officer now owns 4,818 shares in the company, valued at $520,488.54. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 256,373 shares of company stock valued at $27,637,427. Company insiders own 2.00% of the company’s stock.

Institutional Trading of Cooper Companies

Institutional investors and hedge funds have recently bought and sold shares of the stock. Citizens Financial Group Inc. RI grew its position in shares of Cooper Companies by 11.7% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 6,588 shares of the medical device company’s stock valued at $727,000 after acquiring an additional 688 shares during the period. Advisors Asset Management Inc. increased its position in Cooper Companies by 24.6% during the third quarter. Advisors Asset Management Inc. now owns 34,639 shares of the medical device company’s stock worth $3,822,000 after buying an additional 6,839 shares during the last quarter. Segall Bryant & Hamill LLC lifted its position in shares of Cooper Companies by 21.5% in the third quarter. Segall Bryant & Hamill LLC now owns 106,421 shares of the medical device company’s stock valued at $11,742,000 after buying an additional 18,839 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Cooper Companies in the third quarter valued at approximately $1,154,000. Finally, Tranquility Partners LLC boosted its stake in shares of Cooper Companies by 7.1% during the 3rd quarter. Tranquility Partners LLC now owns 9,341 shares of the medical device company’s stock worth $1,031,000 after acquiring an additional 620 shares during the period. Institutional investors own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.